Q-omics provides the consensus-scored CIDECP1 profile across patient tissues and cancer cell-line models. CIDECP1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CIDECP1 is differentially expressed in 11, with the highest sampling consensus in KIRP. Additionally, CIDECP1 RNA expression shows 18,035 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, KIRP, and ACC as cancer lineages where CIDECP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CIDECP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CIDECP1 survival associations across molecular data types. CIDECP1 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CIDECP1 RNA expression–survival associations across cancer types. High CIDECP1 expression shows unfavorable associations in KICH, LIHC, ACC, MESO and KIRC, but favorable associations in UVM. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CIDECP1 RNA expression.
This table summarizes CIDECP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for CIDECP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CIDECP1 shows lower tumor expression in THCA and higher tumor expression in KIRP, LIHC, HNSC, UCEC and CHOL. The KIRP box plot shows higher CIDECP1 RNA expression in tumor versus normal tissue (log2 FC = +0.593, t-test p < 0.001).
This table shows molecular features associated with CIDECP1 in patient tissues and cancer cell lines. In patient samples, CIDECP1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
